Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ospedale Pediatrico Bambino Gesu' is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, SZPERKA, MICHAEL EDWARD, who accounts for the 1 busiest examiner pending office action. The prosecution is currently contained within 1 distinct art unit, focusing the technical dialogue on 1 set of institutional standards. This concentration simplifies the administrative task of monitoring patent office communications.
With 1 pending office action, the administrative overhead is minimal. The practitioner can focus entirely on the specific issues raised by 1 distinct examiner. This lack of complexity across examiners or art units allows for a precise response strategy. By operating within 1 distinct art unit, the applicant can ensure their technical disclosures meet the specific expectations of that unit. The legal team can dedicate their efforts to the 1 busiest examiner pending office action to resolve any outstanding objections.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZPERKA, MICHAEL EDWARD | 1 | 62.6% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266493 | CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES | SZPERKA, MICHAEL EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266493 | CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES | SZPERKA, MICHAEL EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18266493 | CAR T CELLS FOR TREATING CD19+, CD20+ OR CD22+ TUMORS OR B-CELL DERIVED AUTO-IMMUNE DISEASES | SZPERKA, MICHAEL EDWARD | 1641 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOspedale Pediatrico Bambino Gesu' has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael Edward Szperka has the most, with 1 of Ospedale Pediatrico Bambino Gesu''s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
